首页|艾司西酞普兰联合脑电生物反馈方法治疗抑郁症疗效及对血清细胞因子的影响

艾司西酞普兰联合脑电生物反馈方法治疗抑郁症疗效及对血清细胞因子的影响

扫码查看
目的 探讨艾司西酞普兰联合脑电生物反馈方法治疗抑郁症患者疗效及对血清细胞因子水平的影响。方法 收集2021年4月至2023年4月浙江省温州市第七人民医院诊治的80例抑郁症患者等临床相关资料,根据不同治疗方案将其分为2组。其中对照组39例接受艾司西酞普兰治疗,观察组41例接受艾司西酞普兰联合脑电生物反馈方法治疗。治疗8周后评估2组疗效,并比较2组治疗前、治疗8周后汉密尔顿抑郁量表(HAMD)评分、匹兹堡睡眠质量指数(PSQI)评分、血清炎性细胞因子水平及神经功能相关因子水平。结果 观察组临床总有效率[93%(38/41)]高于对照组[77%(30/39)](x2=4。196,P<0。05);观察组治疗后PSQI评分[(9。4±1。6)分]均低于对照组[(11。7±2。0)分](t=4。012,P均<0。05);观察组治疗后脑源性神经营养因子(BDNF)、去甲肾上腺素(NE)、5-羟色胺(5-HT)[(40±8)μg/ml、(11。0±2。0)μg/ml、(127±10)ng/ml]水平高于对照组[(32±5)μg/ml、(8。4±1。6)μg/ml、(106±9)ng/ml](t=3。732、3。002、3。214,P 均<0。05);观察组治疗后白细胞介素(IL)-8、IL-2、肿瘤坏死因子-α(TNF-α)[(5。3±0。7)pg/ml、(4。5±0。8)μg/ml、(13。0±1。1)pg/ml]水平低于对照组[(6。8±0。9)pg/ml、(5。2±1。1)μg/mL、(14。4±1。4)pg/ml](t=3。721、4。012、3。114,P均<0。05)。结论 艾司西酞普兰联合脑电生物反馈方法治疗抑郁症患者血清细胞因子明显改善,疗效确切,值得临床推广。
Effects of escitalopram combined with EEG biofeedback in the treatment of depression patients and its impact on serum cytokine levels
Objective To explore the efficacy of escitalopram combined with EEG biofeedback in the treatment of depression patients and its impact on serum cytokine levels.Methods A total of 80 patients with depression treated at Wenzhou Seventh People's Hospital from April 2021 to April 2023 were collected and divided into a control group and an observation group based on different treatment plans.Among them,the control group(39 cases)received treatment with escitalopram,while the observation group(41 cases)received treatment with escitalopram combined with EEG biofeedback.After 8 weeks of treatment,the efficacy of both groups was evaluated.The Hamilton Depression Rating Scale(HAMD)scores,Pittsburgh Sleep Quality Index(PSQI)scores,serum inflammatory cytokine levels,and neurological function related factor levels were compared between two groups before and 8 weeks after treatment.Results The total clinical effective rate of the observation group[93%(38/41)]is higher than that of the control group[77%(30/39)](x2=4.196,P<0.05);The PSQI score of the observation group after treatment was lower than that of the control group[(9.4±1.6)points vs(11.7±2.0)points],(t=4.012,P<0.05).After treatment,the levels of brain-derived neurotrophic factor(BDNF),serotonin(5-HT),norepinephrine(NE),and serotonin(5-HT)in the observation group were higher than those in the control group[(40±8)μg/ml,(11.0±2.0)μg/ml,(127±10)ng/ml]vs[(32±5)μg/ml,(8.4±1.6)μg/ml,(106±9)ng/ml](t=3.732,3.002,3.214,all P<0.05).The levels of interleukin-8(IL-8),interleukin-2(IL-2),and tumor necrosis factor α(TNF)-α in the observation group were lower than those in the control group[(5.3±0.6)pg/ml,(4.5±0.8)μg/ml,(13.0±1.1)pg/ml]vs[(6.8±0.9)pg/ml,(5.2±1.1)μg/ml,(14.4±1.4)pg/ml](t=3.721,4.012,3.114,all P<0.05).Conclusion The combination of escitalopram and EEG biofeedback therapy significantly improves serum cytokines in patients with depression,and has a definite therapeutic effect,which is worthy of clinical promotion.

EscitalopramNeurofeedbackDepressive disorderSerum cytokines

胡淑静、陈聪聪、叶鑫武、林智远

展开 >

温州市第七人民医院心身科,浙江温州 325000

温州市第七人民医院普通精神科,浙江温州 325000

温州市第七人民医院老年精神科,浙江温州 325000

艾司西酞普兰 神经反馈 抑郁症 血清细胞因子

浙江省温州市科研项目

Y20210768

2024

中国药物与临床
中国医院协会

中国药物与临床

影响因子:0.846
ISSN:1671-2560
年,卷(期):2024.24(7)